Search | Clinical Trials Finder

Conditions: Lung Cancer
Interventions: gemcitabine HCL, pemetrexed disodium; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Biological + 2 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 470
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 352 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions: azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions: Taxotere (Docetaxel), Alimta (Pemetrexed); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Non-small Cell Lung Cancer
Interventions: Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 67
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • Alhambra, California + 64 more

Conditions: Esophageal Cancer
Interventions: carboplatin, Pemetrexed, conventional surgery, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 90
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more

Conditions: Lung Cancer
Interventions: Alimta; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: CC-5013, pemetrexed; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Orlando, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more

Conditions: Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
Interventions: Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT); Drug · Procedure · Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Cancer
Interventions: pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Cancer
Interventions: LY2603618, Desipramine, Pemetrexed, Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 150
States / cities: Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more

Conditions: Trophoblastic Neoplasms, Uterine Neoplasms, Hydatidiform Mole, Choriocarcinoma
Interventions: Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma, Carcinoma, Non-Small- Cell Lung
Interventions: SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Interventions: IAM1363; Drug
Lead sponsor: Iambic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 41
States / cities: Prescott, Arizona • Hot Springs, Arkansas • Springdale, Arkansas + 36 more

Conditions: Untreated Advanced Non-Small Cell Lung Cancer
Interventions: Avastin, Alimta; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Lung Cancer
Interventions: Gemcitabine, Pemetrexed, Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non Small Cell Lung Cancer
Interventions: Nivolumab, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 57
States / cities: Glendale, Arizona • Los Angeles, California • Denver, Colorado + 48 more

Conditions: Advanced Solid Tumors
Interventions: BMS-986408, Nivolumab, Ipilimumab, Platinum-doublet chemotherapy, Rabeprazole; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • Hackensack, New Jersey • Houston, Texas

Conditions: Mesothelioma
Interventions: Nintedanib, Pemetrexed, Cisplatin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pemetrexed, Cetuximab, Docetaxel; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 61
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 58 more

Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions: Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more

Search by objective public record fields.

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Trial for Patients With Gestational Trophoblastic Disease

A Study of SEA-CD40 Given With Other Drugs in Cancers

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

A Phase 1/1b Study of IAM1363 in HER2 Cancers

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Nintedanib (BIBF 1120) in Mesothelioma

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors